Vera Therapeutics Inc - Class A
Research Vera Therapeutics Inc - Class A (VERA) on Bullrun: market cap USD 2.53B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVERA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.53B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 121.03M
- Free cash flow-USD 106.67M
Valuation Snapshot
latest market cap is USD 2.53B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 299.62M | -USD 241.73M | n/a | -4.66 | USD 354.73M | USD 74.84M | USD 604.52M |
| FY2024 | USD 0 | -USD 152.15M | -USD 135.65M | n/a | -2.75 | USD 92.65M | USD 50.69M | USD 577.16M |
| FY2023 | n/a | -USD 95.99M | -USD 92.24M | n/a | -2.25 | USD 45.68M | USD 49.88M | USD 101.69M |
| FY2022 | n/a | -USD 89.06M | -USD 67.66M | n/a | -3.35 | USD 43.46M | USD 24.81M | USD 76.91M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.53B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.61B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.69B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 683.38M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 535.17M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 568.54M | n/a | n/a | n/a |
About Vera Therapeutics Inc - Class A
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vera Therapeutics Inc - Class A's market cap?
Vera Therapeutics Inc - Class A's market capitalization is USD 2.53B.
What does Vera Therapeutics Inc - Class A do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.